This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q05.2 | Special Copayment Reduction: V179 |
| B. Synonyms | Lumbar spina bifida with hydrocephalus | lumbosacral spina bifida with hydrocephalus |
| C. Adult onset | Very low — as a congenital spinal malformation, it is in principle diagnosed in the fetal or neonatal period; first onset in adulthood is extremely rare. |
| 1. History | History of spina bifida; discovery of folic acid prevention (1991); MOMS fetal surgery trial (2011). |
| 2. Causes | Folate deficiency, multifactorial inheritance, maternal diabetes, obesity, anticonvulsants; hydrocephalus: Chiari II malformation. |
| 3. Genetics | MTHFR, PCP pathway; multifactorial inheritance; recurrence risk 2–5%; high-dose folic acid prevention. |
| 4. General epidemiology | 1 in 1,000–2,000 births; Special Copayment Reduction V179; slight sex difference. |
| 5. Pathophysiology | Failure of neural tube closure; two-hit theory; mechanisms of Chiari II malformation and hydrocephalus. |
| 6. Symptoms | Lower limb paralysis (by level), hydrocephalus symptoms, neurogenic bladder and bowel |
| 7. Signs | Cystic defect at the lesion site; neurological findings; signs of hydrocephalus (if present) |
| 8. Screening | MSAFP, detailed prenatal ultrasound (lemon and banana signs), fetal MRI. |
| 9. Diagnosis | Prenatal confirmation; postnatal neurological, imaging, urological, and orthopedic evaluation. |
| 10. Treatment | Spinal cord closure (prenatal/postnatal); hydrocephalus shunt (if present); CIC; rehabilitation. |
| 11. Prognosis | Lumbar: moderate; ambulation with assistive devices possible (L3~L4); protecting renal function is key |
| 12. Prevention | Folic acid (general 400–800 μg; high-risk 4,000 μg); risk factor management. |
| 13. References | Mitchell LE et al. 2004 and 9 other references |
Spina bifida is one of the oldest congenital malformations in the history of human medicine. The term 'spina bifida' is known to have been first used in 1641 by the 17th-century Dutch physician Nicolaas Tulp (1593–1674), expressing in Latin the condition of a vertebra split in two. In the early 18th century, the Italian anatomist Giovanni Battista Morgagni described in detail the pathological anatomy of spina bifida and its association with hydrocephalus. In the 19th century, surgical treatment was attempted, but results were poor because of infection and technical limitations.
In the mid-20th century, the introduction of the ventriculoperitoneal shunt (VP shunt) and antibiotics dramatically improved treatment outcomes for spina bifida with hydrocephalus. In 1965, Hibbard and Smithells first proposed an association between folate deficiency and neural tube defects, and in 1991 the UK MRC Vitamin Study confirmed in a randomized controlled trial that folic acid supplementation before pregnancy reduces recurrence of neural tube defects by about 72%. Mandatory folic acid fortification of grain products was subsequently implemented in many countries, significantly lowering the incidence of spina bifida.
In prenatal diagnosis, the introduction of maternal serum alpha-fetoprotein (MSAFP) testing in 1972 and the spread of high-resolution prenatal ultrasound from the 1980s onward meant that most open spina bifida came to be diagnosed prenatally. The MOMS randomized controlled trial published in 2011 demonstrated that prenatal myelomeningocele closure (fetal surgery) significantly improves neurological outcome compared with postnatal surgery, shifting the paradigm of spina bifida treatment. Today, the worldwide standard for spina bifida management is collaboration among pediatric neurosurgery, neurology, urology, orthopedics, rehabilitation medicine, and developmental pediatrics within a multidisciplinary spina bifida clinic.
Thoracic/lumbar/sacral/unspecified spina bifida with hydrocephalus differ in clinical characteristics depending on lesion level, and each is classified under its own ICD-10 code (Q05.1–Q05.4). In Korea, multidisciplinary spina bifida clinics are also operated mainly at major children's hospitals, and registration under Special Copayment Reduction V179 allows medical cost support.
Spina bifida is a neural tube defect (NTD) caused by failure of the neural tube closure process in early pregnancy (about 17–30 days after fertilization, 5–6 weeks of gestation). Its causes are divided into genetic factors, maternal nutritional and metabolic factors, environmental factors, and multifactorial interactions.
Folate deficiency: folic acid deficiency in early pregnancy is the most important preventable risk factor for spina bifida. Folic acid is an essential nutrient for DNA synthesis, cell division, and one-carbon metabolism, and adequate folic acid intake before and in early pregnancy (400–800 μg per day; 4,000 μg for high-risk groups) lowers the incidence of spina bifida by about 50–70%.
Genetic factors: spina bifida is a multifactorial disease; the MTHFR 677C→T polymorphism, folate receptor gene variants, and variants in planar cell polarity (PCP) pathway genes (VANGL1, VANGL2, etc.) are associated with increased risk of spina bifida. With a family history, the recurrence risk is about 4–8 times that of the general population.
Maternal factors: maternal diabetes (poor glycemic control in early pregnancy), maternal obesity (BMI > 30), use of anticonvulsants (valproic acid, carbamazepine), and high fever in early pregnancy (38°C or higher) increase the risk of spina bifida.
Etiology of hydrocephalus: hydrocephalus arises through combined mechanisms including Chiari II malformation (herniation of the cerebellum and brainstem through the foramen magnum), aqueductal stenosis, and fourth ventricle outlet obstruction. The higher the lesion level, the more severe the Chiari II malformation and the higher the rate and severity of associated hydrocephalus.
Spina bifida is a disease of multifactorial inheritance, arising from complex interactions of multiple genetic polymorphisms and environmental factors rather than a single gene mutation. The risk of recurrence within families is higher than in the general population, but it does not follow a typical Mendelian pattern of inheritance.
Folate metabolism genes: the MTHFR c.677C→T polymorphism (p.Ala222Val) reduces enzyme activity and raises blood homocysteine, increasing the risk of spina bifida about 1.5–2-fold. Variants in folate metabolism enzyme genes such as FOLR1 (folate receptor 1) and MTHFD1 are also associated with neural tube defects.
PCP pathway genes: VANGL1, VANGL2, CELSR1, FZD3, and others are essential for convergent extension movements during neural tube closure, and variants in these genes are found in about 1–3% of patients with spina bifida.
Recurrence risk: 1 child with spina bifida: recurrence risk in the next pregnancy about 2–5%. 2 affected: about 10–15%. One parent affected: about 4–8% for children. In high-risk groups, high-dose folic acid (4,000 μg/day) supplementation from before pregnancy greatly reduces the risk of recurrence.
Spina bifida is the most common neural tube defect worldwide, occurring in about 1 in 1,000–2,000 births. Incidence by country differs greatly depending on folic acid supplementation policies and the rate of pregnancy termination after prenatal diagnosis. For spina bifida with hydrocephalus (Q05.0–Q05.4), hydrocephalus accompanies about 80–90% of all open spina bifida. The incidence in Korea is estimated at about 4–6 per 10,000 births, and registration under Special Copayment Reduction V179 allows medical cost support. Sex differences are slight, and it occurs in all ethnic groups worldwide.
Spina bifida arises from failure of neural tube closure at about 17–30 days of gestation; neural tube closure is a zipper-like process proceeding simultaneously from several initiation sites. The level of spina bifida (cervical/thoracic/lumbar/sacral) is determined by the site of closure failure. Two-hit hypothesis: ① the primary developmental defect due to failure of neural tube closure + ② secondary damage from exposure to amniotic fluid in utero cause the neurological impairment. Chiari II malformation arises from abnormal posterior fossa development due to herniation of the spinal cord and causes non-communicating hydrocephalus through impaired cerebrospinal fluid flow. Neurogenic bladder arises from loss of sacral nerve (S2–S4) function below the lesion.
Lumbar spina bifida is the most common lesion location among spina bifida cases, and partial or complete paralysis of the lower limbs and neurogenic bladder and bowel are the main clinical problems. The extent of preserved lower limb function varies with the lumbar lesion level, with neural function lost sequentially from L1~L2 to L5~S1.
Lower limb function: L1~L2 lesions: some hip flexion possible, complete paralysis below the knee. L3 lesions: hip flexion and adduction and knee extension possible, paralysis below the ankle. L4 lesions: knee extension and flexion possible, ankle dorsiflexion possible. L5 lesions: most ankle and toe function preserved. Many patients with lumbar spina bifida (L3~L4 lesions) are capable of community ambulation using assistive devices (AFO, KAFO).
Hydrocephalus symptoms: hydrocephalus also accompanies lumbar spina bifida, but in some cases it is less severe than with cervical or thoracic lesions. Symptoms of increased intracranial pressure (headache, nausea and vomiting, bulging fontanelle) and symptoms related to Chiari II malformation may appear. Early treatment of hydrocephalus is important for cognitive prognosis.
Neurogenic bladder: sacral (S2~S4) neural control is lost or weakened, so neurogenic bladder develops in almost all patients. Urinary incontinence, residual urine, recurrent urinary tract infections, and reduced renal function due to vesicoureteral reflux (VUR) are the main problems. Early introduction of CIC is key to protecting renal function.
Neurogenic bowel: constipation and fecal incontinence are characteristic, and a regular bowel management program (diet, stool softeners, suppositories, anal irrigation) is needed.
Sensory loss: with sensory loss below the lesion, there is a risk of failing to notice pressure injuries (pressure ulcers), burns, and trauma. Skin care and regular examinations are important.
The main physical signs of lumbar spina bifida are determined by the lumbar-level lesion and hydrocephalus.
Neurological signs: flaccid paralysis or paresis of the lower limbs (extent varying with lesion level), sensory loss, and decreased or absent deep tendon reflexes are observed. Preservation of the knee reflex at the L3~L4 level and partial preservation of the ankle reflex at the L4~L5 level are possible. Loss of the anal reflex and weakness of the anal sphincter appear.
Orthopedic signs: hip dislocation (depending on lesion level and muscle imbalance), clubfoot (common in lumbar spina bifida), leg length discrepancy, and foot deformities are observed. With growth, scoliosis and abnormal lumbar lordosis may develop.
Hydrocephalus signs: macrocephaly, a bulging anterior fontanelle, and the sunset sign may appear in infants. In lumbar spina bifida, Chiari II malformation is less severe than with cervical or thoracic lesions, but Chiari symptoms (headache, upper limb paresthesia, dysphagia) are rarely reported.
Imaging findings: MRI identifies lumbar-level myelomeningocele, tethered cord, syringomyelia, ventricular enlargement due to hydrocephalus, and Chiari II malformation. Urologic ultrasound evaluates for hydronephrosis and vesicoureteral reflux (VUR).
Prenatal screening for spina bifida follows a stepwise approach: maternal serum alpha-fetoprotein (MSAFP, 15–22 weeks of gestation; positive threshold ≥ 2.0–2.5 MoM), detailed prenatal ultrasound at 18–22 weeks (spinal defect, lemon sign, banana sign, ventriculomegaly), and additional fetal MRI if abnormal. Prenatal ultrasound has a sensitivity of 95% or higher for detecting open spina bifida. Fetal MRI precisely assesses the lesion level, degree of Chiari II malformation, and severity of hydrocephalus, providing important information for surgical decisions and prognostic counseling. Amniotic fluid AFP and AChE testing is performed as an adjunct when ultrasound findings are unclear.
Diagnosis of spina bifida is confirmed prenatally by a stepwise approach of prenatal MSAFP → detailed ultrasound → fetal MRI, and completed after birth by neurological evaluation, brain and spine MRI, urological evaluation, and orthopedic evaluation. Immediately after birth, motor and sensory function below the lesion level, the anal reflex, and bladder function are evaluated to establish the extent of loss of neurological function. Brain MRI identifies hydrocephalus, Chiari II malformation, and associated brain malformations, and spinal MRI evaluates the lesion level, tethered cord, and syringomyelia. Urodynamic testing characterizes the neurogenic bladder and determines the indications for starting CIC.
Treatment of spina bifida with hydrocephalus requires a multidisciplinary approach including prenatal or postnatal spinal cord closure, hydrocephalus surgery (VP shunt or ETV), neurogenic bladder management (CIC, anticholinergics), orthopedic treatment, and neurodevelopmental support. Prenatal surgery (fetal surgery): based on the MOMS trial (2011), performed at 19–25 weeks of gestation in selected cases; it reverses Chiari II malformation, reduces the need for shunting, and improves lower limb motor function. Postnatal surgery: closure of the spinal defect within 24–48 hours. Treatment of hydrocephalus: VP shunt or ETV. Neurogenic bladder: CIC + anticholinergics (key to protecting renal function). Orthopedics: orthoses, surgical correction. Rehabilitation: physical therapy, occupational therapy, speech therapy, neuropsychological assessment, and learning support.
The prognosis of lumbar spina bifida varies with the lesion level, whether hydrocephalus is controlled, and the management of neurogenic bladder. Overall, it is more favorable than cervical or thoracic spina bifida, and ambulation with assistive devices is possible in many patients.
Ambulation prognosis: about 50~70% of patients with L3~L4 lesions achieve community ambulation. With L4~L5 lesions, many patients are capable of independent walking with an AFO. With upper lumbar (L1~L2) lesions, most are limited to therapeutic ambulation. Increased energy expenditure, progression of lower limb deformities, and spinal cord retethering affect ambulatory function.
Renal function prognosis: with early introduction of CIC and use of anticholinergics to manage neurogenic bladder appropriately, the proportion of patients with preserved renal function has increased. However, progression to vesicoureteral reflux, pyelonephritis, and chronic renal failure still occurs in patients who do not receive treatment or have poor follow-up. Renal health through adulthood strongly affects overall quality of life and life expectancy.
Intellectual function: when hydrocephalus is appropriately treated, about 70~80% of patients maintain borderline intelligence or higher. However, learning disabilities (especially in mathematics and concentration) and visuospatial processing disorders in the mild to moderate range are commonly observed, so school support is needed.
The most effective primary prevention of spina bifida is folic acid supplementation before and in early pregnancy. General population: 400–800 μg daily from 1 month before pregnancy until 12 weeks of gestation. High-risk groups (previous NTD pregnancy, family history, diabetes, anticonvulsant use): high-dose 4,000 μg daily from before pregnancy until 12 weeks of gestation. Management of risk factors before pregnancy: glycemic control in maternal diabetes, obesity management, substitution or dose minimization of anticonvulsants such as valproic acid, and avoidance of high fever in early pregnancy. Prenatal care: MSAFP screening, detailed ultrasound, fetal MRI, and pregnancy and delivery planning with the multidisciplinary team. Prevention of complications: early surgery (spinal cord closure, shunting), early introduction of CIC, and regular multidisciplinary follow-up for early detection and management of shunt malfunction, spinal cord retethering, and urological complications.